
FIG. 1


A
EGFR-CT26
MFI
Cetuximab
Anti-EGFR
DBXT001-01
Isotype IgG1
Antibody concentration (nM)
B
HER3-CT26
MFI
Anti-HER3
DBXT001-01
Isotype IgG1
Antibody concentration (nM)
C
NCI-H441 (EGFR WT)
EGFR ++, HER3 ++
MFI
Anti-EGFR
Anti-HER3
DBXT001-01
Isotype IgG1
Antibody concentration (nM)
D
NCI-H1975 (EGFR L858R/T790M)
EGFR ++, HER3 +
MFI
Anti-EGFR
Anti-HER3
DBXT001-01
Isotype IgG1
Antibody concentration (nM)
E
T47D
EGFR +, HER3 ++
MFI
Anti-EGFR
Anti-HER3
DBXT001-01
Isotype IgG1
Antibody concentration (nM)



A
CT26/EGFR
MFI
40000
30000
20000
10000
0
0.001 0.01 0.1 1 10 100 1000
Antibody concentration (nM)
SI-1X6.4
DBXT005-01
Anti-EGFR
Anti-HER3
Isotype IgG1
B
CT26-ERBB3
MFI
60000
40000
20000
0
0.001 0.01 0.1 1 10 100 1000
Antibody concentration (nM)
SI-1X6.4
DBXT005-01
Anti-EGFR
Anti-HER3
Isotype IgG1
C
MDA-MB-468
MFI
1000000
800000
600000
400000
200000
0
0.001 0.01 0.1 1 10 100 1000
Antibody concentration (nM)
SI-1X6.4
DBXT005-01
Anti-EGFR
Anti-HER3
Isotype IgG1
D
BT-474
MFI
50000
40000
30000
20000
10000
0
0.001 0.01 0.1 1 10 100 1000
Antibody concentration (nM)
SI-1X6.4
DBXT005-01
Anti-EGFR
Anti-HER3
Isotype IgG1

FIG. 2



T47D
Endocytosis of antibodies
(MFI of pHrodo-labeled Abs)
40000
30000
20000
10000
0
0.01
0.1
1
10
100
1000
Antibody concentration (nM)
Isotype IgG1
anti-EGFR mAb
anti-HER3 mAb
DBXT001-01

FIG. 3



A
CT26 with EGFR overexpression and HER3 overexpression (48 h)
Total fluorescence integrated intensity
(RCU x µm²/Image)
6×10⁶
4×10⁶
2×10⁶
0
10nM
anti-EGFR mAb
anti-HER3 mAb
DBXT001-01
SI-1X6.4
Isotype IgG1
B
NCI-H1975 (48 h)
Total fluorescence integrated intensity
(RCU x µm²/Image)
1000000
800000
600000
400000
200000
0
60nM
10nM
anti-EGFR mAb
anti-HER3 mAb
DBXT001-01
SI-1X6.4
Isotype IgG1

FIG. 4

A
A431
Total fluorescence area
(RCU × μm²/image)
150000
100000
50000
0
SI-1X6.4
DBXT005-01
Anti-EGFR
Anti-HER3
B
HER3/CT26
Total fluorescence area
(RCU × μm²/image)
800000
600000
400000
200000
0
SI-1X6.4
DBXT005-01
Anti-EGFR
Anti-HER3
C
NCI-H1975
Total fluorescence area
(RCU × μm²/image)
100000
80000
60000
40000
20000
0
SI-1X6.4
DBXT005-01
Anti-EGFR
Anti-HER3
D
SK-BR-3
Total fluorescence area
(RCU × μm²/image)
10000
8000
6000
4000
2000
0
SI-1X6.4
DBXT005-01
Anti-EGFR
Anti-HER3

FIG. 5



OE19
EGFR +, HER3 ++
Blank control group
ADC-1
ADC-2
ADC-6
Tumor volume (mm3)
3000
2000
1000
0
0
10
20
30
Days after administration (day)

FIG. 6



NCI-H441
EGFR ++, HER3 ++
Blank control group
ADC-1
ADC-2
ADC-6
Tumor volume (mm3)
2000
1500
1000
500
0
0
10
20
30
40
Days after administration (day)

FIG. 7



CAL-27
EGFR +++, HER3 +
Blank control group
ADC-1
ADC-2
ADC-6
anti-EGFR mAb
Tumor volume (mm3)
1500
1000
500
0
0
10
20
30
Days after administration (day)

FIG. 8



NCI-H1975 (EGFR L858R/T790M)
EGFR ++, HER3 +
Blank control group
ADC-2
ADC-4
ADC-5
ADC-6
Tumor volume (mm3)
5000
4000
3000
2000
1000
0
0
10
20
30
Days after administration (day)

FIG. 9



OE19
EGFR +, HER3 ++
Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0
10
20
30
Days after administration (day)
Blank control group
ADC-1
ADC-2
ADC-4
ADC-5
ADC-6

FIG. 10



NCI-H1975
Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0
10
20
30
Days after administration (day)
Blank control group
ADC-3
ADC-6
ADC-10

FIG. 11



OE-19
Tumor volume (mm3)
4000
3000
2000
1000
0
0
5
10
15
20
25
Days after administration (day)
Blank control group
ADC-11
ADC-3
ADC-6
ADC-10
ADC-9

FIG. 12



NCI-H1975
Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0
5
10
15
20
25
Days after administration (day)
Blank control group
ADC-12
ADC-9

FIG. 13



OE-19
(EGFR+, HER3 ++)
Tumor volume (mm3)
2000
1500
1000
500
0
0
5
10
15
20
25
Days after administration
Blank control group
ADC-13, 5mg/kg, intravenous injection, administered once
ADC-14, 8mg/kg, intravenous injection, administered once

FIG. 14



A431 (EGFR+++, HER3+)
Tumor volume (mm3)
4000
3000
2000
1000
0
0
5
10
15
20
25
Days after treatment
Blank control group, intravenous injection, administered once
ADC-13, 6mg/kg, intravenous injection, administered once
ADC-14, 6mg/kg, intravenous injection, administered once

FIG. 15



SW620 (EGFR-, HER3++)
Tumor volume (mm3)
3500
3000
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
70
Days after treatment
Blank control group, intravenous injection, administered once every three weeks, for a total of two times
ADC-13, 10 mg/kg, intravenous injection, administered once every three weeks, for a total of two times
ADC-14, 10 mg/kg, intravenous injection, administered once every three weeks, for a total of two times

FIG. 16



SW48 (EGFR++, HER3+)
Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
10
20
30
40
50
Days after treatment
Blank control group, intravenous injection, administered once every three weeks, for a total of two times
ADC-13, 10 mg/kg, intravenous injection, administered once every three weeks, for a total of two times
ADC-14, 10 mg/kg, intravenous injection, administered once every three weeks, for a total of two times

FIG. 17



NCI-H1975 (EGFR L858R/T790M/C797S)
Tumor volume (mm3)
2000
1500
1000
500
0
0
10
20
30
40
Days after treatment
Blank control group, intravenous injection, administered once every three weeks, for a total of two times
ADC-13, 6 mg/kg, intravenous injection, administered once every three weeks, for a total of two times
ADC-14, 6 mg/kg, intravenous injection, administered once every three weeks, for a total of two times

FIG. 18